Paradromics Appoints William J. Marks Jr., MD, as Chief Clinical Officer
Paradromics Strengthens Clinical Leadership with Appointment of Dr. William J. Marks Jr. as Chief Clinical Officer Paradromics Inc., a clinical-stage neurotechnology company developing high-bandwidth brain-computer interface (BCI) systems, has announced…
Catalent and Nanoscope Expand Partnership for MCO-010
Catalent and Nanoscope Therapeutics Expand Partnership to Advance Commercial Readiness of Vision-Restoring Gene Therapy MCO-010 Catalent, Inc., a global leader in development, manufacturing, packaging, and supply solutions for the pharmaceutical…
LTZ Therapeutics Receives FDA IND Clearance for LTZ-232
LTZ Therapeutics Receives FDA Clearance to Begin Clinical Evaluation of LTZ-232 for Advanced Metastatic Colorectal Cancer and Other Solid Tumors LTZ Therapeutics, a clinical-stage biotechnology company focused on developing next-generation…
bioAffinity Technologies Reports Record Quarterly CyPath® Lung Sales
bioAffinity Technologies Reports More Than 200% Growth in CyPath® Lung Sales as Physician Adoption Continues to Accelerate bioAffinity Technologies, Inc., a biotechnology company dedicated to developing innovative, noninvasive diagnostic solutions…
Uniquity Bio Appoints Matthew Hartzell as Chief Financial Officer
Uniquity Bio Strengthens Executive Leadership with Appointment of Matthew Hartzell as Chief Financial Officer Uniquity Bio, a clinical-stage biotechnology company dedicated to developing innovative therapies for immune-mediated and inflammatory diseases,…
Turn Therapeutics Expands GX-03 Phase 2 Program in Atopic Dermatitis
Turn Therapeutics Finalizes Phase 2 Study Design for GX-03 Following Positive Interim Analysis in Atopic Dermatitis Turn Therapeutics, Inc., a clinical-stage biotechnology company focused on developing targeted, non-systemic therapies for…
Genmab Secures EU Approval for TEPKINLY® in Follicular Lymphoma
Genmab Wins European Commission Approval for TEPKINLY® Combination Genmab A/S has announced that the European Commission (EC) has granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab…
Orion and Shilpa Medicare Expand Nivolumab Biosimilar Partnership
Orion and Shilpa Medicare Expand European Nivolumab Biosimilar Partnership Shilpa Medicare Limited has announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and long-term…
Incyte Expands Hematology Portfolio with Vega Therapeutics Acquisition
Incyte Completes $1.25 Billion Acquisition of Vega Therapeutics, Expanding Hematology Portfolio with Late-Stage von Willebrand Disease Therapy VGA039 Incyte has announced the successful completion of its acquisition of Vega Therapeutics,…
PharmaEssentia Wins Health Canada Approval for BESREMi® in Polycythemia Vera
PharmaEssentia Receives Health Canada Approval for BESREMi® to Treat Adults with Polycythemia Vera PharmaEssentia Corporation, a Taiwan-based global biopharmaceutical company specializing in the development of innovative biologic therapies for hematology…
Agenus Reports Landmark BOT+BAL Data at ESMO GI 2026
Agenus Reports Landmark Three-Year Phase 1b Data Showing Durable Survival with Botensilimab Plus Balstilimab in Refractory MSS Metastatic Colorectal Cancer Agenus Inc., a biotechnology company focused on advancing next-generation immuno-oncology…
Elucid Highlights Personalized Cardiovascular Care at SCCT 2026
Elucid to Showcase Next-Generation AI-Powered Coronary CT Technologies and Advance Its CCTA 3.0 Vision at SCCT 2026 Elucid, a medical technology company specializing in artificial intelligence-powered coronary CT angiography (CCTA)…